Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Earnings Season Turns Into Silly Season

Executive Summary

A clinical trial failure at Auris and a revoked patent at Johnson & Johnson that will lead to the emergence of real US biosimilar competition passed virtually unnoticed last week. It's that time of year again.

You may also be interested in...



Stock Watch: Bridgebio’s Endpoint A Bridge Too Far

The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.

Stockwatch: A Biopharma Nativity Play

The cadence of the news in the biopharmaceutical space slowed significantly last week in the run-up to the holidays. In seasonal spirit, Andy “the innkeeper” Smith assigns roles in the Christmas nativity play to those who did come forward – including Ophthotech, Amicus and Lilly.

Auris' Outlook Bleak In Tinnitus After Failure Of Initial Phase III Trial

The Swiss biotech still holds out hope that its NMDA antagonist Keyzilen will hit its primary endpoint in a European Phase III study in acute tinnitus, but a largely US-based first Phase III trial missed both co-primary endpoints.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel